Oruka Therapeutics reported that ORKA-001 achieved complete skin clearance in 63.5% of treated patients at Week 16 in interim data from the ongoing EVERLAST-A Phase 2a trial. The result is a strong clinical efficacy signal for its psoriasis program and may support investor confidence in the drug's development path. The update is positive for the stock, though still early-stage and not yet definitive.
Oruka Therapeutics reported that ORKA-001 achieved complete skin clearance in 63.5% of treated patients at Week 16 in interim data from the ongoing EVERLAST-A Phase 2a trial. The result is a strong clinical efficacy signal for its psoriasis program and may support investor confidence in the drug's development path. The update is positive for the stock, though still early-stage and not yet definitive.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
moderately positive
Sentiment Score
0.62
Ticker Sentiment
